In recent years, B-cell receptor (BCR) inhibitors (such as ibrutinib) have transformed the treatment landscape for CLL. However, a significant challenge remains: some patients experience incomplete responses or eventually develop resistance to these drugs, even without acquiring the common BTK genetic mutations typically associated with drug failure.
